LTI-03

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameLTI-03
Drug Alias NameCaveolin-1 scaffolding protein derived peptideCaveolin-1 scaffold protein-derived 7-amino acid peptideCSP-7LTI-03CSP-4
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionCaveolin-1 replacementsp53-binding protein Mdm-2 inhibitors
TargetsCaveolin-1p53-binding protein Mdm-2
Therapy Area/IndicationsIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Texas At TylerLung Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLung Therapeutics IncRein Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A